Abstract
Recurrent respiratory papillomatosis (RRP) is a benign neoplastic disease of the respiratory tract that is caused by human papilloma virus (HPV). The current standard of care is surgical excision with adjuvant treatment as needed. Multiple adjuvant treatments have been used with some success, but long-term control of disease remains difficult. We report on a case of a patient with a long history of RRP who had stabilized true vocal fold disease while on pembrolizumab for concurrent early stage lung squamous cell carcinoma.
Keywords:
Human papillomavirus; Immunotherapy; Pembrolizumab; Recurrent respiratory papillomatosis.
Published by Elsevier Inc.
MeSH terms
-
Antibodies, Monoclonal, Humanized* / therapeutic use
-
Carcinoma, Squamous Cell / complications
-
Carcinoma, Squamous Cell / therapy
-
Esophageal Squamous Cell Carcinoma / complications
-
Esophageal Squamous Cell Carcinoma / therapy
-
Humans
-
Lung Neoplasms / complications
-
Lung Neoplasms / therapy
-
Male
-
Middle Aged
-
Papillomavirus Infections* / complications
-
Papillomavirus Infections* / drug therapy
-
Respiratory Tract Infections* / complications
-
Respiratory Tract Infections* / drug therapy
-
Vocal Cords / pathology
-
Vocal Cords / surgery
Substances
-
Antibodies, Monoclonal, Humanized
-
pembrolizumab
Supplementary concepts
-
Recurrent respiratory papillomatosis